CD40 and neoplasm: - Enhanced primary CD8+ and CD4+ T-cell responses and tumor protection when vaccinated with the solid nanoemulsion (SN) in comparison to the reference formulation, Aldara® - Co-application of the SN with co-stimulatory ligands such as CD40 ligands, promotes specific T-cell responses in the priming and memory phase, strongly enhancing antitumor protection in mice